299. Cystic fibrosis Clinical trials / Disease details


Clinical trials : 1,696 Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-004063-21-NL
(EUCTR)
24/07/200831/10/2007An open label, exploratory study on the effect of rhBSSL on the fat absorption in patients with cystic fibrosis and pancreatic insufficiency. - N/AAn open label, exploratory study on the effect of rhBSSL on the fat absorption in patients with cystic fibrosis and pancreatic insufficiency. - N/A Cystic fibrosis and pancreatic insufficiency
MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis
Product Name: rhBSSL
Product Code: rhBSSL
INN or Proposed INN: Bucelipase alfa
Trade Name: Nexium 20
Product Name: Nexium
INN or Proposed INN: Esomeprazole
Biovitrum ABNULLNot RecruitingFemale: yes
Male: yes
18Netherlands
2NCT01983774
(ClinicalTrials.gov)
February 20086/11/2013Effect of Proton Pump Inhibitors on CF Pulmonary ExacerbationsEffect of Proton Pump Inhibitors on CF ExacerbationsCystic FibrosisDrug: Esomeprazole;Drug: PlaceboColumbia UniversityNULLTerminated18 Years65 YearsBoth13Phase 2United States